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Introduction {#acn3572-sec-0005}
============

Prior to the availability of high‐resolution magnetic resonance imaging (MRI), Baló\'s concentric sclerosis (BCS) was diagnosed by the presence of large, inflammatory lesions with concentric rings within the brain\'s white matter obtained via autopsy or biopsy.[1](#acn3572-bib-0001){ref-type="ref"}, [2](#acn3572-bib-0002){ref-type="ref"}, [3](#acn3572-bib-0003){ref-type="ref"} BCS was believed to be a destructive focal neuroinflammatory condition and entailed a devastating prognosis.[1](#acn3572-bib-0001){ref-type="ref"}, [4](#acn3572-bib-0004){ref-type="ref"}, [5](#acn3572-bib-0005){ref-type="ref"} With the increasing use of MRI, diagnosis of BCS is now generally based on radiographic findings and identified already early in the course of the disease.[1](#acn3572-bib-0001){ref-type="ref"}, [4](#acn3572-bib-0004){ref-type="ref"}

Characteristic MRI features of Baló‐type lesions comprise circular layers of alternating signal intensity on T~1~‐ or T~2~‐weighted (T~1~w or T~2~w, respectively) images.[1](#acn3572-bib-0001){ref-type="ref"}, [2](#acn3572-bib-0002){ref-type="ref"}, [6](#acn3572-bib-0006){ref-type="ref"} Lesions are typically located within the cerebral white matter, the basal ganglia, pons, cerebellum, and the spinal cord, while they usually spare the U‐fibers.[1](#acn3572-bib-0001){ref-type="ref"}, [2](#acn3572-bib-0002){ref-type="ref"}, [7](#acn3572-bib-0007){ref-type="ref"}, [8](#acn3572-bib-0008){ref-type="ref"}

Clinical symptoms of BCS are described as (sub)acute onset of hemiparesis, hemianopia, or hemihypoesthesia, but also headache, encephalopathic symptoms, and seizures.[4](#acn3572-bib-0004){ref-type="ref"}, [6](#acn3572-bib-0006){ref-type="ref"}, [7](#acn3572-bib-0007){ref-type="ref"} BCS patients treated with immunomodulatory and immunosuppressive drugs show recovery from symptoms and prolonged survival, similar to multiple sclerosis (MS).[1](#acn3572-bib-0001){ref-type="ref"}, [4](#acn3572-bib-0004){ref-type="ref"}, [6](#acn3572-bib-0006){ref-type="ref"}, [7](#acn3572-bib-0007){ref-type="ref"}, [8](#acn3572-bib-0008){ref-type="ref"} In light of an overlap of neuropathological and clinical findings,[1](#acn3572-bib-0001){ref-type="ref"}, [3](#acn3572-bib-0003){ref-type="ref"}, [8](#acn3572-bib-0008){ref-type="ref"}, [9](#acn3572-bib-0009){ref-type="ref"} the question arises as to whether BCS is a rare variant of MS, a disease entity of its own, or a clinical and radiological phenotype comprising different disease entities. Ultrahigh‐field MRI at 7 Tesla (7 T) benefits from high spatial resolution and enhanced susceptibility effects that improve the visualization, detection, and morphological description of inflammatory brain lesions.[10](#acn3572-bib-0010){ref-type="ref"}, [11](#acn3572-bib-0011){ref-type="ref"}, [12](#acn3572-bib-0012){ref-type="ref"}, [13](#acn3572-bib-0013){ref-type="ref"} More precisely, in T~2~\*w MRI, a central vessel can frequently be depicted within MS lesions, and the presence of a central vessel is believed to be typical for MS lesions.[10](#acn3572-bib-0010){ref-type="ref"}, [11](#acn3572-bib-0011){ref-type="ref"}, [13](#acn3572-bib-0013){ref-type="ref"} Given the unresolved nosologic association of BCS with MS, we set out to investigate the similarities and differences of BCS and MS lesions via high spatial resolution 7 T MRI. We did so in a prospective observational study of 10 BCS patients and 10 MS patients to investigate whether ultrahigh field lesion characteristics that are considered typical of MS are also present in BCS patients. Moreover, we compared additional clinical and paraclinical findings in BCS and in MS patients, including the course of the disease (re‐scan and telephone interview), and testing for autoantibodies against aquaporin‐4 (AQP4), and myelin oligodendrocyte glycoprotein (MOG‐IgG) that have been reported in patients with large or tumefactive brain lesions.[14](#acn3572-bib-0014){ref-type="ref"}, [15](#acn3572-bib-0015){ref-type="ref"}, [16](#acn3572-bib-0016){ref-type="ref"}, [17](#acn3572-bib-0017){ref-type="ref"}

Methods {#acn3572-sec-0006}
=======

Study participants {#acn3572-sec-0007}
------------------

Ten BCS patients were prospectively recruited from the neuroimmunology outpatient clinics of the Experimental and Clinical Research Center and the NeuroCure Clinical Research Center at Charité -- Universitätsmedizin Berlin. The patients had been referred to Charité for obtaining a second opinion. The study design is outlined and detailed in Figure [1](#acn3572-fig-0001){ref-type="fig"}. Inclusion criteria were age 18--65 years and diagnosis of BCS that was based on conventional MRI findings (at least two hyperintense areas separated by one hypo‐/isointense rim on T~2~w images)[1](#acn3572-bib-0001){ref-type="ref"}, [3](#acn3572-bib-0003){ref-type="ref"}, [8](#acn3572-bib-0008){ref-type="ref"}, [18](#acn3572-bib-0018){ref-type="ref"}, [19](#acn3572-bib-0019){ref-type="ref"}, [20](#acn3572-bib-0020){ref-type="ref"} and confirmed by histopathological analyses in three patients. The only exclusion criterion was contraindication to undergo 7 T MRI. For comparison, the 10 best‐matching patients regarding disease duration, age, and sex with relapsing remitting MS (RRMS) for whom 7 T MRI scans were available were selected from the NeuroCure neuroimaging database as controls. The study was conducted in conformity with the Declaration of Helsinki and approved by the ethics committee of Charité -- Universitätsmedizin Berlin. All participants provided written informed consent.

![Overview. A timeline of the overall study design (top) is displayed in addition to clinical and paraclinical findings of all individual patients with Baló concentric sclerosis (bottom). The overall study design graphic represents mean time intervals between the single time points. Patients were recruited in the outpatient clinic of the Charité -- Universitätsmedizin Berlin after the diagnosis of Baló concentric sclerosis. Three patients with Baló concentric sclerosis underwent biopsy and/or surgical resection prior to study enrollment. Two patients had relapses during the follow‐up period (asterisks). 7 T, 7 Tesla MRI; 3 T, 3 Tesla MRI.](ACN3-5-900-g001){#acn3572-fig-0001}

Clinical and paraclinical characterization {#acn3572-sec-0008}
------------------------------------------

Medical records of the BCS patients were used to obtain data on the initial clinical presentation, disability measured through the Expanded Disability Status Scale (EDSS),[21](#acn3572-bib-0021){ref-type="ref"} CSF oligoclonal bands, immunomodulatory treatment as well as disease duration. In addition, BCS patients underwent clinical examination and EDSS assessment at the time of 7 T MRI (±30 days). Disease duration was defined as time between first symptoms (onset) and 7 T MRI. The follow‐up period started with the completion of the 7 T examination and ended with a telephone interview (Fig. [1](#acn3572-fig-0001){ref-type="fig"}). In order to investigate a possible association with neuromyelitis optica spectrum disorders or anti‐MOG antibody‐associated encephalomyelitis, serum samples from all 10 BCS patients were tested for serum AQP4‐ and MOG‐IgG at the University Hospital Heidelberg[14](#acn3572-bib-0014){ref-type="ref"} using a cell‐based assay (CBA).[14](#acn3572-bib-0014){ref-type="ref"} CBA employed human embryonic kidney 293 cells transfected with human full‐length MOG as previously described[14](#acn3572-bib-0014){ref-type="ref"}; nontransfected cells were used as control substrate.

MR imaging acquisition {#acn3572-sec-0009}
----------------------

Ultrahigh‐field MR images of BCS and RRMS patients were acquired using a 7 T Siemens whole‐body scanner (Magnetom, Siemens, Erlangen, Germany) and a 24‐channel receiver head coil (Nova Medical, Wilmington, MA) equipped with a birdcage volume coil for transmission. The imaging protocol included a two‐dimensional T~2~\*w fast low‐angle shot sequence (T~2~\*w, FLASH, TE = 25 msec; TR = 1820 msec; spatial resolution = 0.5 × 0.5 × 2 mm^3^, supratentorial coverage), a three‐dimensional T~1~‐weighted magnetization‐prepared rapid gradient echo sequence (T~1~w, MPRAGE, TE = 2.98 msec; TR = 2300 msec; inversion time \[TI\] = 900 msec; spatial resolution = 1.0 ×1.0 × 1.0 mm^3^, whole‐brain coverage), a three‐dimensional fluid‐attenuated inversion recovery sequence (FLAIR, TE = 398 msec; TR = 8010 msec; TI = 2150msec, spatial resolution = 1.0 × 1.0 × 1.0 mm^3^), and a three‐dimensional gradient echo flow‐compensated susceptibility‐weighted imaging sequence (SWI, TE = 14 msec, TR = 25 msec, flip angle = 12°; spatial resolution =0.5 × 0.5 × 1.0 mm^3^, supratentorial coverage) that yields magnitude, phase, and reconstructed SW images.

In addition, a very high‐resolution 2D T~2~\*w FLASH sequence (TE = 25 msec; TR = 1820 msec; spatial resolution = 0.2 × 0.2 × 2 mm^3^) was done in nine patients with Baló‐type lesions. For information on the 3 T MRI protocol please see Data [S1](#acn3572-sup-0005){ref-type="supplementary-material"}.

Image analysis {#acn3572-sec-0010}
--------------

The 7 T MR images were analyzed by two experienced investigators (Julia Wanner, Tim Sinnecker) who did not have any knowledge of clinical details (EDSS, age, sex) in consensus reading, using the OsiriX software package (OsiriX Foundation, Genève, Switzerland, version 3.8.1). BCS lesion morphology, including the existence of a central venous vessel, a T~2~\*w hypointense rim, and intralesional T~2~\*w signal alterations, was assessed in consensus reading. A central vein in a Baló‐type lesion was defined as a vein that runs in equidistance to the border through the inner circle of a Baló‐type lesion.

In addition, the number of additional non‐Baló lesions in BCS patients was determined. Hereby, a brain lesion was defined as a hyperintense area of at least three voxels on FLAIR and T~2~\*w images. The "central vein sign" was assessed in these lesions according to NAIMS criteria in consensus reading.[22](#acn3572-bib-0022){ref-type="ref"} In addition, the involvement of U‐fibers, the existence of Dawson\'s fingers, and Barkhof criteria were assessed.[23](#acn3572-bib-0023){ref-type="ref"}

The analysis of the 3 T MR images included the assessment of the MRI part (dissemination in space and time) of the 2010 MS diagnostic panel criteria,[24](#acn3572-bib-0024){ref-type="ref"} based on 3 T MR image taken at the beginning of the study. The follow‐up 3 T MRI images were analyzed with regard to newly developed lesions and whether a patient met positive MS diagnostic criteria.[24](#acn3572-bib-0024){ref-type="ref"}

Statistical analysis {#acn3572-sec-0011}
--------------------

A Mann--Whitney *U*‐test was used to detect differences between MS and BCS patients. *P* \< 0.05 were considered statistically significant.

Results {#acn3572-sec-0012}
=======

Study participants {#acn3572-sec-0013}
------------------

Ten patients with Baló‐type lesions detected by MRI at disease onset were included (nine female). Mean age was 35.2 (SD = 7.9 years, range 27--49 years), and the mean disease duration -- from disease onset to acquisition of the 7 T MR image -- was 20.6 months (SD = 24.4 months, range 3--67 months). BCS patients presented with a median EDSS of 3.75 (range 2.0--4.0). The median clinical follow‐up was 31.0 months (range 21--38 months).

As a control group, 10 patients with relapsing--remitting MS (RRMS) with comparable sex and age distribution and EDSS scores were included (nine female; mean ± SD age 31.7 ± 6.8 years, range 23--43 years, *P *=* *0.28; mean ± SD disease duration 31.2 ± 34.3 months, range 2--113 months, *P *=* *0.53; median EDSS 1.5, range 0--2.0). More clinical details of the BCS patients are presented in Table [1](#acn3572-tbl-0001){ref-type="table"} and Figure [1](#acn3572-fig-0001){ref-type="fig"}.

###### 

Characteristics of patients with Baló\'s concentric sclerosis at study onset

  ID     Age (years)   Sex   Disease duration (in months)   EDSS   Onset                                 Symptoms of presentation                                         Acute therapy                                                                             Months until initiation of DMT   Disease modifying therapy (DMT)   CSF white blood cells/μL (total)   OCB
  ------ ------------- ----- ------------------------------ ------ ------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------- --------------------------------- ---------------------------------- --------------
  \#1    28            W     8                              2.5    Stroke‐like                           Aphasia, hemihypesthesia (right side), vertigo, fatigue          Methyl‐prednisolone 1 g for 4 days                                                        19                               Dimethyl fumarate                 1                                  No
  \#2    27            M     3                              2.5    Stroke‐like                           Hemiparesis (right side)                                         Methyl‐prednisolone 1 g for 5 days and five times plasmapheresis                          4                                Dimethyl fumarate                 12                                 Yes (Type 2)
  \#3    32            W     45                             2.0    Stroke‐like                           Sensomotor hemiparesis (right side)                              Methyl‐prednisolone 1 g for 5 days                                                        65                               Natalizumab                       8                                  Yes (Type 2)
  \#4    44            W     67                             4.0    Stroke‐like                           Paresis of the left arm                                          Methyl‐prednisolone 1 g for 5 days                                                        2                                Glatiramer acetate                13                                 Yes (Type 2)
  \#5    45            W     53                             4.0    Subacute progressive (all symptoms)   Encephalopatic symptoms (cognitive deficits, social isolation)   Methyl‐prednisolone 1 g for 5 days and immuneglobuline                                    4                                Glatiramer acetate                4                                  Yes (Type 2)
  \#6    49            W     6                              4.0    Stroke‐like                           Facial and hemiparesis, left side                                Methyl‐prednisolone 1 g for 5 days                                                        1                                Natalizumab                       19                                 No
  \#7    33            W     10                             4.0    Stroke‐like                           Hemiparesis, (left side), dysarthria                             Methyl‐prednisolone 1 g for 5 days, plasmapheresis and three cycles of cyclophosphamide   11                               Azathioprine                      2                                  Yes (Type 2)
  \#8    35            W     5                              4.0    Stroke‐like                           Hemiparesis (left side)                                          Methyl‐prednisolone 1 g for 5 days                                                        1                                Glatiramer acetate                \>10                               Yes (Type 2)
  \#9    31            W     6                              2.5    Subacute progressive (all symptoms)   Prosopagnosia, vertigo, hemihypesthesia (right side)             Methyl‐prednisolone 1 g for 2 days                                                        4                                Natalizumab                       5                                  Yes (Type 2)
  \#10   28            W     3                              3.5    Stroke‐like                           Hemiparesis (left side), dysarthria, fatigue                     Methyl‐prednisolone 1 g for 3 days                                                        4                                Interferon beta‐1a                6                                  Yes (Type 2)

ID, identification number; EDSS, Expanded Disability Status Scale; Disease duration, time between onset, and 7 T intervention; OCB, oligoclonal bands; Oligoclonal bands Type 2, Oligoclonal IgG restricted to CSF.
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Clinical findings in patients with Baló‐type lesions {#acn3572-sec-0014}
----------------------------------------------------

Hemiparesis and/or hemihypoesthesia were the most frequent symptoms at disease onset (*n *=* *7) in BCS patients. Eight of 10 patients showed an acute onset of symptoms within hours to maximum symptom development, while all 10 MS patients exhibited a subacute onset within days to maximum symptom development. The majority of BCS patients (*n *=* *7) had no further relapses until the end of observation, whereas three patients had relapses (Table 3). There was no difference in age (*P *=* *0.67), gender (*P *=* *0.83), disease duration (*P *=* *1), and median duration until the follow‐up examination (*P *=* *1) between BCS patients with or without relapses. None of the BCS patients reported neurological symptoms prior to the symptomatic BCS lesion. All BCS patients received methylprednisolone pulse therapy as an acute relapse treatment at onset. In seven out of 10 patients, symptoms were mitigated during methylprednisolone pulse therapy (Table [1](#acn3572-tbl-0001){ref-type="table"}). Plasmapheresis was done in two patients. Symptoms in these two patients incompletely recovered during plasmapheresis. Cyclophosphamide cycles and immunoglobulin therapy was given to one patient and had no clinical effect. After the relapse therapy, treatment regimens of BCS patients comprised immunomodulation with glatiramer acetate (*n *=* *3), interferon beta‐1a (*n *=* *1), dimethyl fumarate (*n *=* *3), natalizumab (*n *=* *2) as well as immunosuppression with cyclophosphamide and subsequently azathioprine (*n *=* *1) (Table [1](#acn3572-tbl-0001){ref-type="table"}). Relapses during treatment are summarized in Table 3.

Lesion morphology of Baló‐type lesions in 7 Tesla MRI {#acn3572-sec-0015}
-----------------------------------------------------

MR imaging findings are presented in Figure [S1](#acn3572-sup-0001){ref-type="supplementary-material"} and summarized in Table [2](#acn3572-tbl-0002){ref-type="table"}. Lesion morphology at the time of the 7 T MR imaging was partially concealed in three patients due to surgical resection or biopsy. MR imaging before biopsy or surgical resection is shown in Figure [S2](#acn3572-sup-0002){ref-type="supplementary-material"}. All but the two partially resected Baló‐type lesions had characteristic lesions with concentric rings on 7 T MR images (Fig. [2](#acn3572-fig-0002){ref-type="fig"}, Fig. [S1](#acn3572-sup-0001){ref-type="supplementary-material"}). The rim thickness varied across subjects: Four patients had rather thick rims of more than 0.5 cm, and four patients had rims smaller than 0.5 cm (Fig. [S3](#acn3572-sup-0003){ref-type="supplementary-material"}). In greater detail, T~2~\*w and SWI hypointense rim‐like structures were regularly observed at the border between T~2~\*w and FLAIR hyperintense areas (*n *=* *8). These T~2~\*w and FLAIR hyperintense areas corresponded to T~1~w hypointense lesion areas. In one Baló‐type lesion, brain tissue in‐between T~2~w hyperintense rims layers was characterized by T~2~\*w and T~1~w gray‐scale intensity values similar to normal appearing white matter (Fig. [S4](#acn3572-sup-0004){ref-type="supplementary-material"}) as reported previously.[25](#acn3572-bib-0025){ref-type="ref"} In addition, lesions in four out of 10 BCS patients (patients \#1, \#4, \#5, and \#7) had an inhomogeneous intralesional T~2~\*w signal distribution, which is suggestive of microhemorrhages or small ectatic venous vessels within the lesions (Fig. [3](#acn3572-fig-0003){ref-type="fig"}). All Baló‐type lesions (*n *=* *10) had spatial contact to the lateral ventricles and the periventricular white matter preserving cortical areas or U‐fibers.

###### 

MRI findings -- lesion morphology and localization in BCS and MS

  ID                   Lesion number (BCS: additional lesions to BCS)   Central vein (Baló lesions)   Central vein (non‐Baló lesions)   Dawson\'s fingers   Barkhof criteria (brain MRI)   U‐fiber involvement   Cortical lesions
  -------------------- ------------------------------------------------ ----------------------------- --------------------------------- ------------------- ------------------------------ --------------------- ------------------
  BCS group                                                                                                                                                                                                      
  BCS \#1              3                                                Yes                           1 (33%)                           Yes                 No                             No                    No
  BCS \#2              4                                                Yes                           2 (50%)                           No                  No                             No                    No
  BCS \#3              11                                               No                            9 (82%)                           Yes                 Yes                            No                    No
  BCS \#4              0                                                N/A                           N/A                               No                  No                             No                    No
  BCS \#5              4                                                N/A                           2 (50%)                           No                  No                             No                    No
  BCS \#6              62                                               Yes                           14 (24%)                          No                  No                             No                    No
  BCS \#7              0                                                Yes                           N/A                               No                  No                             No                    No
  BCS \#8              3                                                Yes                           1 (33%)                           Yes                 No                             No                    No
  BCS \#9              8                                                Yes                           4 (50%)                           No                  No                             No                    No
  BCS \#10             2                                                Yes                           2 (100%)                          No                  No                             No                    No
  RRMS control group                                                                                                                                                                                             
  RRMS \#1             1                                                N/A                           1                                 No                  No                             No                    No
  RRMS \#2             2                                                N/A                           2                                 Yes                 No                             No                    No
  RRMS \#3             17                                               N/A                           11                                Yes                 Yes                            Yes                   No
  RRMS \#4             36                                               N/A                           22                                Yes                 Yes                            Yes                   No
  RRMS \#5             4                                                N/A                           4                                 No                  No                             No                    1
  RRMS \#6             40                                               N/A                           33                                Yes                 Yes                            Yes                   5
  RRMS \#7             5                                                N/A                           2                                 Yes                 No                             No                    No
  RRMS \#8             1                                                N/A                           1                                 Yes                 No                             No                    No
  RRMS \#9             5                                                N/A                           4                                 Yes                 No                             No                    No
  RRMS \#10            93                                               N/A                           77                                Yes                 Yes                            Yes                   No

BCS, Baló\'s concentric sclerosis; MRI, magnetic resonance imaging; MS, multiple sclerosis; ID, identification number; RRMS, relapsing--remitting MS; Barkhof criteria, \>3/4 positive; Possible central vein was not detectable due to operation or biopsy (not applicable, n.a.).
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![Central intralesional vein in Baló concentric sclerosis. A distinct venous vessel is clearly visible within the center of the inner ring of one exemplary Baló‐type lesion on 7 T, T~2~\*w (A), SWI (B) and MR phase images (C). 7 T, 7 Tesla; T~2~\*w, two‐dimensional T~2~\*‐weighted fast low‐angle shot (FLASH); SWI, three‐dimensional gradient echo flow‐compensated susceptibility‐weighted imaging.](ACN3-5-900-g002){#acn3572-fig-0002}

![Inhomogeneous intralesional T~2~\*w signal distribution within an exemplary Baló‐type lesion. 7 T T~2~\*w images of one exemplary lesion (patient \#7) are presented demonstrating T~2~\* hypointense structures (arrows) within the lesion. These signal alterations potentially indicate microhemorrhages or small ectatic venous vessels. 7 T, 7 Tesla; T~2~\*w, two‐dimensional T~2~\*‐weighted fast low‐angle shot (FLASH).](ACN3-5-900-g003){#acn3572-fig-0003}

Central veins within Baló‐type lesions {#acn3572-sec-0016}
--------------------------------------

A distinct venous vessel was clearly visible in the center of seven Baló‐type lesions (Fig. [2](#acn3572-fig-0002){ref-type="fig"}), and not detectable in one Baló‐type lesion. In two BCS patients, the central vein sign was not analyzable due to surgical resection.

Comparison between non‐Baló lesions in BCS patients and RRMS controls {#acn3572-sec-0017}
---------------------------------------------------------------------

Next, we compared imaging findings between non‐Baló lesions in the BCS group and brain lesions in the 10 matched RRMS patients.

In the BCS group, 97 non‐Baló lesions were identified in eight of 10 patients (Table [2](#acn3572-tbl-0002){ref-type="table"}). In the RRMS control group, a total number of 204 lesions (median 5 ± 29 lesions per patient, range 1--93) were analyzed.

First, the existence of a central vein was analyzed in these lesions. In BCS, 36 of the 97 (37%) non‐Baló lesions were encircled around a central vein that was visible on T~2~\*w images (Fig. [4](#acn3572-fig-0004){ref-type="fig"}). The median proportion of lesions with a central vein in additional non‐Baló lesions per patient was 42% (range 0--100%). More specifically, four BCS patients were characterized by a proportion of at least 40% of lesions with a central vein (patients \#2, \#3, \#9, \#10). In two additional BCS patients (patients \#1, \#8) a clearly visible central vein was evident in one of three non‐Baló lesions. The central vein sign was detectable in less than 40% of lesions and thus considered negative in BCS patient \#6 (the proportion of lesions with a central vein was 24%). Patients \#4 and \#7 had no non‐Baló lesions at all. In patient \#5, a vein was found in the center of two of four lesions, but the lesions did not follow the course of the vein.

![MS‐typical lesions in Baló concentric sclerosis. A T~2~\*w image is displayed showing multiple MS‐typical lesions (circle) with a central vein in addition to a single but prominent Baló‐type lesion (arrow). T~2~\*w, two‐dimensional T~2~\*‐weighted fast low‐angle shot (FLASH); MS, multiple sclerosis.](ACN3-5-900-g004){#acn3572-fig-0004}

In the control group, nine of 10 RRMS patients had at least 40% or more lesions with a central vein (156 of 204 lesions \[=77%\], median 4.0 lesions per patient, range 0--77).

Second, U‐fiber involvement and the existence of cortical lesions were assessed. Cortical lesions or involvement of U‐fibers were absent in all BCS patients. By contrast, two RRMS patients exhibited cortical gray matter lesions (six of 204 lesions, 3%), and an involvement of U‐fibers was present in four RRMS patients.

In addition, Dawson\'s finger‐shaped lesions were found in three of 10 BCS patients (patients \#1, \#3, \#8; Fig. [4](#acn3572-fig-0004){ref-type="fig"}), and eight of 10 RRMS patients.

Spinal cord MRI and follow up at 3 T {#acn3572-sec-0018}
------------------------------------

About nine BCS patients underwent standardized 3 T MRI within 6 weeks before or after the baseline 7 T scan. The 3 T scan included spinal cord MRI in four patients (Table [3](#acn3572-tbl-0003){ref-type="table"}). No spinal cord lesions were detected (Table [3](#acn3572-tbl-0003){ref-type="table"}).

###### 

3 T MRI and clinical follow‐up in patients with Baló concentric sclerosis

  ID                                           Baseline (MRI)   Follow‐up (MRI)   Follow‐up (clinical)   Follow‐up                                                                                       
  -------------------------------------------- ---------------- ----------------- ---------------------- ----------- ----- ----- ----- ----- ---- ------------------------------------------------------ -----
  \#1                                          Yes              Yes               Asymptomatic           N/A         Yes   No    N/A   Yes   34   No further relapses                                    Yes
  \#2                                          Yes              No                No                     N/A         No    No    N/A   No    33   No further relapses                                    No
  \#3                                          Yes              Yes               Yes                    No          Yes   N/A   N/A   N/A   38   Five relapses in total, one relapse under therapy      Yes
  \#4                                          Yes              No                No                     N/A         No    No    N/A   No    33   No further relapses                                    No
  \#5                                          Yes              No                Symptomatic            No          No    No    No    No    31   No further relapses                                    No
  \#6                                          Yes              Yes               Asymptomatic           N/A         Yes   N/A   N/A   N/A   31   Four relapses in total, three relapses under therapy   Yes
  \#7                                          No               No                No                     No          No    N/A   N/A   N/A   22   No further relapses                                    No
  \#8                                          Yes              No                No                     No          No    N/A   N/A   N/A   21   No further relapses                                    No
  \#9                                          Yes              No                N/A                    N/A         N/A   N/A   N/A   N/A   21   Two relapses, no relapse under therapy                 Yes
  \#10[a](#acn3572-note-0007){ref-type="fn"}   Yes              No                Symptomatic            N/A         No    N/A   N/A   N/A   29   No further relapses                                    No

ID, identification number; MRI, magnetic resonance imaging; N/A, not available; DiS, dissemination in space; DiT, dissemination in time; symptomatic, contrast enhancement correlates with the clinical presentation; asymptomatic, contrast enhancement does not correlate with the clinical presentation.

Baseline data of patient ID 10 were derived from 7 T MRI. Follow‐up: time between 7 T intervention and telephone interview.
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Follow‐up 3 T MRI was performed in four patients -- after 12 months in patient \#2, \#4, \#5, and after 18 months in patient \#1 (Table [3](#acn3572-tbl-0003){ref-type="table"}). In these 4 patients, no new lesions were detected at follow‐up.

Evaluation of MS diagnostic panel criteria in BCS patients {#acn3572-sec-0019}
----------------------------------------------------------

We investigated whether BCS patients fulfilled diagnosis of MS as defined by the 2010 MS diagnostic panel criteria.[24](#acn3572-bib-0024){ref-type="ref"} At study baseline, four of 10 BCS patients fulfilled the 2010 MS diagnostic panel criteria (patient \#1, \#3, \#6, and \#9, Table [3](#acn3572-tbl-0003){ref-type="table"}). In particular, all four patients fulfilled the MRI criteria for dissemination in space. The MRI criteria for dissemination in time were positive in three patients (patients \#1, \#3, and \#6). Clinical criteria for dissemination in time were positive in patients \#3, \#6, and \#9.

During the follow‐up period, two of the four BCS patients who met MS diagnostic criteria at baseline had further relapses (patients \#3 and \#6). By contrast, no new lesions or relapses were detectable in the BCS patients who were initially negative with respect to MS diagnostic criteria. In other words, none of these BCS patients met MS diagnostic criteria during follow‐up.

One limitation is that the assessment of the 2010 MRI criteria for dissemination in time was not possible at baseline in one BCS patient because no contrast agent was given.

Histopathological findings in three BCS patients {#acn3572-sec-0020}
------------------------------------------------

Brain biopsy and/or surgical resection was done prior to this study in three BCS patients (Table [4](#acn3572-tbl-0004){ref-type="table"}). The biopsy decision was independently made by the treating center specialized in neurology. Specimens of all three BCS patients were characterized by demyelinating processes with almost complete loss of myelin. Furthermore, a predominately T‐cell--driven perivascular lymphocyte infiltration (*n *=* *2) as well as activated microglia (*n *=* *2), astrogliosis with hypertrophic astrocytes (*n* = 2) and a reduction of axonal density (*n *=* *2) were regularly observed within the lesion. While in one patient the oligodendrocytes had enlarged nuclei, oligodendrocytes were relatively well preserved in another. The axons in one patient were predominantly preserved. In one patient, astrocytes containing fragmented nuclei (Creutzfeldt--Peters cells) were found.

###### 

Histopathological findings in patients with Baló concentric sclerosis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  ID    Demyelination                             Histological characteristics                                       Cell infiltration
  ----- ----------------------------------------- ------------------------------------------------------------------ ---------------------------------------------
  \#3   Sharply limited, inactive demyelination   Astrogliosis\                                                      T‐cell dominating and diffuse infiltration\
                                                  Hypertrophic astrocytes\                                           Plenty of macrophages
                                                  Activated microglia\                                               
                                                  Oligodendrocytes with hypertrophic nuclei in the outlying areas\   
                                                  Reduced axons                                                      

  \#4   Limited demyelination                     Astroctopathy with two or more nuclei\                             T‐cells perivascular
                                                  Astrocytopathy surrounding the lesion\                             
                                                  Axons relatively well‐preserved, occasionally hypertrophic         

  \#5   Demyelination inside the lesion           Astrogliosis\                                                      Lymphocytes\
                                                  Hypertrophic astrocytes\                                           Plasma cells\
                                                  Creutzfeldt--Peters cells\                                         Foamy macrophages
                                                  Activated microglia\                                               
                                                  Relatively well‐preserved oligodendrocytes inside the lesion\      
                                                  Reduced axons                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

ID, identification number.
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Biomarkers in patients with Baló‐type lesions {#acn3572-sec-0021}
---------------------------------------------

Eight of 10 BCS patients had type 2 oligoclonal bands in CSF but not in serum indicative of intrathecal IgG synthesis (all three BCS patients with relapses; three of the four BCS patients with positive 2010 MS diagnostic criteria; Table [1](#acn3572-tbl-0001){ref-type="table"}).[26](#acn3572-bib-0026){ref-type="ref"} None of the BCS patients had antibodies to AQP4 or MOG antibodies in serum.

Discussion {#acn3572-sec-0022}
==========

In this prospective ultrahigh‐field MRI study we investigated lesion characteristics in 10 BCS patients in comparison to 10 typical RRMS patients without Baló‐type lesions. A central intralesional vein -- characteristic for MS lesions -- was detectable within the majority of Baló‐type lesions, and a periventricular lesion distribution was common in both disease types. In contrast to RRMS controls, lesions in the cortical gray matter and subcortical U‐fibers were absent in all patients with BCS. Some lesions in BCS patients were characterized by signs of peripheral ectatic veins. In alignment with our in vivo results, previous ex vivo investigations indicated that the inflammation expands from a central venule into the surrounding white matter in both MS‐ and BCS‐derived lesions.[6](#acn3572-bib-0006){ref-type="ref"}, [27](#acn3572-bib-0027){ref-type="ref"} In contrast to MS, alternating patterns of demyelination and preservation seem to proceed periodically in BCS, causing the characteristic large multilayer lesions.[7](#acn3572-bib-0007){ref-type="ref"}, [19](#acn3572-bib-0019){ref-type="ref"}, [20](#acn3572-bib-0020){ref-type="ref"}, [28](#acn3572-bib-0028){ref-type="ref"}, [29](#acn3572-bib-0029){ref-type="ref"}, [30](#acn3572-bib-0030){ref-type="ref"} However, the pathophysiologic underpinnings of this lesion pattern are currently not well understood. Several mechanisms have been suggested, including alternating gradients of proinflammatory and anti‐inflammatory agents, oxidative stress resulting in hypoxia‐like tissue injury with a combination of protective and damaging factors, astrocytopathy as well as loss of aquaporin 4 and connexin 43 which causes oligodendrocytopathy.[1](#acn3572-bib-0001){ref-type="ref"}, [2](#acn3572-bib-0002){ref-type="ref"}, [19](#acn3572-bib-0019){ref-type="ref"}, [30](#acn3572-bib-0030){ref-type="ref"}, [31](#acn3572-bib-0031){ref-type="ref"}

In this study, an inhomogeneous intralesional T~2~\*w signal intensity was observed in four of 10 Baló‐type lesions, which may be related to microhemorrhages or small ectatic venous vessels within the lesions. Similar findings including microhemorrhages and ectatic veins in T~2~w hyperintense regions of a Baló‐type lesion were previously described in a 7 T case report.[32](#acn3572-bib-0032){ref-type="ref"} The visibility of venous structures on T~2~\*w images of 7 T is dependent on the degree of deoxygenation of the venous blood, since only desoxyhemoglobine causes signal loss as a consequence of the magnetic susceptibility effects.[12](#acn3572-bib-0012){ref-type="ref"} In line with previous MR spectroscopy and diffusion‐weighted MRI studies,[7](#acn3572-bib-0007){ref-type="ref"}, [32](#acn3572-bib-0032){ref-type="ref"} these imaging findings may reflect alterations in oxygen demand and are in line with the hypothesis of hypoxia‐induced tissue degeneration during Baló‐type lesion formation. In addition, a potential overlap of BCS with other atypical inflammatory demyelinating syndromes like tumefactive demyelination as well as MOG‐IgG‐ or AQP4‐IgG‐associated brain damage has been proposed.[3](#acn3572-bib-0003){ref-type="ref"}, [33](#acn3572-bib-0033){ref-type="ref"}, [34](#acn3572-bib-0034){ref-type="ref"} In our study, Creutzfeldt--Peters cells, a histopathological feature of tumefactive demyelination, were detectable in one biopsy.[3](#acn3572-bib-0003){ref-type="ref"}, [33](#acn3572-bib-0033){ref-type="ref"} AQP4‐IgG and MOG‐IgG were negative in all BCS patients, suggesting that these antibodies do not play a key role in the pathogenesis of BCS.

Aside from these pathophysiological considerations another key aspect of this study was to compare clinical and paraclinical findings between patients with MS and BCS. Similar to MS patients, our BCS patients often exhibited positive oligoclonal bands (*n *=* *8), Dawson\'s fingers (*n *=* *3), and a visible central vein in 36 of 97 non‐Baló lesions. While lesions that appeared to be typical MS lesions were also found in previous reports,[4](#acn3572-bib-0004){ref-type="ref"}, [5](#acn3572-bib-0005){ref-type="ref"}, [9](#acn3572-bib-0009){ref-type="ref"}, [20](#acn3572-bib-0020){ref-type="ref"} oligoclonal bands have been reported only in approximately two‐thirds of BCS patients.[5](#acn3572-bib-0005){ref-type="ref"}, [6](#acn3572-bib-0006){ref-type="ref"}, [7](#acn3572-bib-0007){ref-type="ref"}, [35](#acn3572-bib-0035){ref-type="ref"} Wallner‐Blazek et al. assumed the coexistence of MS‐type lesions in patients with atypical demyelinating lesions, including Baló‐type lesions, as an indicator of future disease activity.[9](#acn3572-bib-0009){ref-type="ref"}

On this background, one might speculate that BCS is a heterogeneous disease of which one subgroup shares common features with MS (oligoclonal bands, MS‐type lesions, relapses) while a different subgroup is characterized by a different etiopathogenesis. Our data is not conclusive on this issue: On one hand, three BCS patients met the diagnostic criteria for MS at the onset of the study, and two of these had further relapses. In addition, all three BCS patients with a relapsing--remitting disease course indeed exhibited additional non‐Baló lesions with a central vein, and two displayed positive oligoclonal bands. On the other hand, we also observed similar findings in the group without further relapses during the period of observation, and a recent systematic review did not describe differences between BCS patients with and without oligoclonal bands.[35](#acn3572-bib-0035){ref-type="ref"} Thus, a longer follow‐up is needed to ultimately determine the prognostic relevance of a positive central vein sign, Dawson\'s fingers, or oligoclonal bands in BCS.

One clear difference between BCS and RRMS controls, however, was that in our study -- in line with the literature (Table [5](#acn3572-tbl-0005){ref-type="table"})[4](#acn3572-bib-0004){ref-type="ref"}, [5](#acn3572-bib-0005){ref-type="ref"}, [6](#acn3572-bib-0006){ref-type="ref"}, [7](#acn3572-bib-0007){ref-type="ref"}, [18](#acn3572-bib-0018){ref-type="ref"} -- the majority of BCS patients showed a stroke‐like onset with relatively severe symptoms like hemiparesis and hemihypesthesia.

###### 

Review of the literature: time course of development of symptoms

  References                                                                                   Acute onset                                                    Subacute onset
  -------------------------------------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------------------------------
  Karaarslan et al.[6](#acn3572-bib-0006){ref-type="ref"}                                      5 Baló concentric sclerosis patients with an acute onset       
  Mowry et al.[7](#acn3572-bib-0007){ref-type="ref"}, [8](#acn3572-bib-0008){ref-type="ref"}   1 Baló concentric sclerosis patient with a stroke‐like onset   
  Wang et al.[4](#acn3572-bib-0004){ref-type="ref"}                                            6 Baló concentric sclerosis patients with an acute onset       1 Baló concentric sclerosis patient with progressive clinical manifestation for a week
  Purohit et al.[5](#acn3572-bib-0005){ref-type="ref"}                                         1 Baló concentric sclerosis patient with an acute onset        
  Chen et al.[18](#acn3572-bib-0018){ref-type="ref"}                                           2 Baló concentric sclerosis patients with acute onset          4 Baló concentric sclerosis patients with a subacute onset
  15/20 Baló concentric sclerosis patients                                                     5/20 Baló concentric sclerosis patients                        

John Wiley & Sons, Ltd

Our study is not free from limitations. The small sample size and the short follow‐up period in some patients complicate the investigation of potential prognostic MR biomarkers. Blinding to the BCS diagnosis was obviously not fully achievable during MRI analysis, given the characteristic brain lesions in BCS. Finally, various treatment regimens most likely influenced clinical disease courses.

In summary, this is the first investigation of BCS patients using ultrahigh‐field MRI in a prospective observational study. We observed differences between Baló patients and patients with RRMS, for instance, regarding lesion location, involvement of cortical gray matter and intralesional T~2~\*w signal inhomogeneities. Nevertheless, a central vein and Dawson\'s fingers, which are both typical of MS, were also present in some BCS patients. This suggests that both diseases share at least some pathophysiological commonalities. Although further prospective studies are needed, our investigations show that BCS is not necessarily a disease with a devastating prognosis. Indeed, more than two‐thirds of the BCS patients included in our study had a clinically stable disease course without further relapses during the time span that we covered.
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###### 

**Figure S1.** 7 T MR images at study onset. 7 T T~2~\*w images acquired at study onset of all patients with Baló concentric sclerosis are presented. Each Baló‐type lesion is framed. BCS patients who underwent a biopsy are marked with \*. 7 T, 7 Tesla; T~2~\*w, two‐dimensional T~2~\*‐weighted fast low‐angle shot (FLASH).
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Click here for additional data file.

###### 

**Figure S2.** MR images prior to surgical resection or biopsy. The figure illustrates MR images that were acquired prior to biopsy or surgical resection showing contrast‐enhancing Baló‐type lesions in all three patients (patients \#3, \#4, and \#5). Key: (A) fluid‐attenuated inversion recovery (FLAIR) images; (B) T~1~w contrast‐enhanced images.
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Click here for additional data file.

###### 

**Figure S3.** Lesion morphology of two exemplary Baló‐type lesions. While lesion (A) is characterized by rather thin rims, lesion (B) exhibits a single thicker outer rim. The relevance of such different lesion morphologies is unknown yet. Please note the biopsy area in (A) (asterisk).
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Click here for additional data file.

###### 

**Figure S4.** Intralesional T~2~\*w and T~1~w gray‐scale values of Baló‐type lesions. T~2~\*w images (A and C) and T~1~w images (B and D) of two patients with Baló‐type lesions are displayed. In general, Baló‐type lesions were characterized by alternating layers of T~2~\* hyperintense and hypointense layers. Hereby, T~2~\*w hyperintense areas usually correspond to strongly T~1~w hypointense areas (A and B). In one patient (C and D), brain tissue in‐between T~2~w hyperintense rims appeared preserved (arrow in C and D), given that it was characterized by T~2~\*w and T~1~w gray‐scale intensity values similar to normal appearing white matter. T~2~\*w, two‐dimensional T~2~\*‐weighted fast low‐angle shot (FLASH); T~1~w, three‐dimensional T~1~‐weighted magnetization prepared rapid gradient echo (MPRAGE).
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Click here for additional data file.

###### 

**Data S1.** MR imaging acquisition of 3 T MRI sequences. The MR imaging acquisition of the 3 T MRI sequences (MPRAGE, T~2~‐weighted images and FLAIR) are shown. 3 T, 3‐Tesla MRI; MPRAGE, three‐dimensional T~1~‐weighted magnetization prepared rapid gradient echo; FLAIR, fluid‐attenuated inversion recovery images.

###### 

Click here for additional data file.
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